Running Early Phase Oncology Clinical Trials is a balancing act that can be complex and challenging, even when things go right. A lot of factors, such as budget and resource availability, changes in regulatory guidelines and an ever-shifting treatment landscape, can impact how aggressive drug developers are in pushing through their early phase studies. In this panel discussion we will examine how to maximise the value of Early Phase Oncology studies whilst balancing cost and resource constraints all while keeping patients at the forefront.
Chair:
Bryce Davies, Sr Director, Head of Asia Phase 1 Oncology Academy, IQVIA Biotech
Panellists:
Megan Hooton, President, IQVIA Biotech
Dr. Chris Burns, CEO, Amplia
Prof. Hui Gan. Head, Cancer Therapies and Biology Laboratory and Co-Director, Centre for Research Excellence in Brain Cancer, Olivia Newton-John Cancer Research Institute; Director, Cancer Clinical Trials Centre, Austin Health
Holly Stefl, Chief Commercial Officer, P74 Bio
In Partnership with:
